﻿<?xml version="1.0" encoding="utf-8"?>
<rss version="2.0">
  <channel>
    <title>Aidsmap news - English</title>
    <description> </description>
    <link>http://www.aidsmap.com/Aidsmap-news-English/page/1260794/</link>
    <language>en-gb</language>
    <copyright>NAM Publications - 2012</copyright>
    <pubDate>Sun, 05 Feb 2012 01:33:05 GMT</pubDate>
    <lastBuildDate>Sun, 05 Feb 2012 01:33:05 GMT</lastBuildDate>
    <docs>http://backend.userland.com/rss</docs>
    <generator>RSS.NET: http://www.rssdotnet.com/</generator>
    <item>
      <title>For patients with HIV viral load is key in immune response to yellow fever vaccine</title>
      <description>Viral load is the only factor associated
with a poorer antibody response to the yellow fever vaccine in patients with
HIV, according to a French study published in the online edition of the Journal of Acquired Immune Deficiency
Syndromes.
For patients vaccinated after diagnosis
with HIV, an undetectable viral load was the “unique determinant” of</description>
      <link>http://www.aidsmap.com/For-patients-with-HIV-viral-load-is-key-in-immune-response-to-yellow-fever-vaccine/page/2229704/</link>
      <category>Health problems</category>
      <category>Immunisations</category>
      <category>Latin America</category>
      <category>Must see</category>
      <category>Sub-Saharan Africa</category>
      <category>Travel</category>
      <category>Western and Central Europe</category>
      <author>Michael Carter</author>
      <guid isPermaLink="True">http://www.aidsmap.com/For-patients-with-HIV-viral-load-is-key-in-immune-response-to-yellow-fever-vaccine/page/2229704/</guid>
      <pubDate>Thu, 02 Feb 2012 08:10:00 GMT</pubDate>
    </item>
    <item>
      <title>Contraception in HIV prevention trials: injectable hormonal methods more effective?</title>
      <description>Women
using injectable (hormonal) contraceptives had a significantly lower rate of
pregnancy compared to those using oral contraception in a major HIV prevention study, researchers report in the advance online edition of AIDS.
However, the same study also found that women who used an injectable hormonal contraceptive method were at higher risk of</description>
      <link>http://www.aidsmap.com/Contraception-in-HIV-prevention-trials-injectable-hormonal-methods-more-effective/page/2229312/</link>
      <category>Conception</category>
      <category>Contraception</category>
      <category>Sub-Saharan Africa</category>
      <author>Carole Leach-Lemens</author>
      <guid isPermaLink="True">http://www.aidsmap.com/Contraception-in-HIV-prevention-trials-injectable-hormonal-methods-more-effective/page/2229312/</guid>
      <pubDate>Thu, 02 Feb 2012 07:10:00 GMT</pubDate>
    </item>
    <item>
      <title>Men who have sex with men may now be the highest-risk group for HIV in Africa, IAVI study suggests</title>
      <description>Men who have sex with men may now be at considerably higher
risk of acquiring HIV than other at-risk groups such as female sex workers or
young people of either sex, if findings by the International AIDS Vaccine
Initiative (IAVI) of HIV incidence at two centres in Kenya can be generalised to other
populations.
The</description>
      <link>http://www.aidsmap.com/Men-who-have-sex-with-men-may-now-be-the-highest-risk-group-for-HIV-in-Africa-IAVI-study-suggests/page/2234346/</link>
      <category>Epidemiology and behaviour</category>
      <category>Kenya</category>
      <category>Men who have sex with men (MSM)</category>
      <category>Sex workers</category>
      <category>South Africa</category>
      <author>Gus Cairns</author>
      <guid isPermaLink="True">http://www.aidsmap.com/Men-who-have-sex-with-men-may-now-be-the-highest-risk-group-for-HIV-in-Africa-IAVI-study-suggests/page/2234346/</guid>
      <pubDate>Wed, 01 Feb 2012 11:30:00 GMT</pubDate>
    </item>
    <item>
      <title>HIV care providers in US struggling to cope with rising patient numbers</title>
      <description>HIV doctors in the US are struggling to
meet the demands of a rising patient caseload, according to the findings of a
national survey. 
Two-thirds of HIV treatment providers
reported an increase in patient numbers, and a third reported difficulties
being reimbursed for the care they provided. 
The second annual HealthHIV State of Primary</description>
      <link>http://www.aidsmap.com/HIV-care-providers-in-US-struggling-to-cope-with-rising-patient-numbers/page/2232782/</link>
      <category>Delivery of care</category>
      <category>Must see</category>
      <category>United States</category>
      <author>Michael Carter</author>
      <guid isPermaLink="True">http://www.aidsmap.com/HIV-care-providers-in-US-struggling-to-cope-with-rising-patient-numbers/page/2232782/</guid>
      <pubDate>Wed, 01 Feb 2012 08:40:00 GMT</pubDate>
    </item>
    <item>
      <title>Quarter of men resume sex before wounds from circumcision fully healed in Zambian study</title>
      <description>Approximately a quarter of men undergoing circumcision
resume sexual activity before their wounds have fully healed, Zambian research
published in the online edition of AIDS
shows. 
Most of the men reporting the early resumption of sexual
activity engaged in unprotected sex, often with multiple partners.
The investigators calculated that early resumption of sexual
activity at this</description>
      <link>http://www.aidsmap.com/Quarter-of-men-resume-sex-before-wounds-from-circumcision-fully-healed-in-Zambian-study/page/2227154/</link>
      <category>Circumcision</category>
      <category>Must see</category>
      <category>Zambia</category>
      <author>Michael Carter</author>
      <guid isPermaLink="True">http://www.aidsmap.com/Quarter-of-men-resume-sex-before-wounds-from-circumcision-fully-healed-in-Zambian-study/page/2227154/</guid>
      <pubDate>Tue, 31 Jan 2012 09:00:00 GMT</pubDate>
    </item>
    <item>
      <title>Raltegravir/Truvada HIV PEP regimen well tolerated with no infections after its use</title>
      <description>Raltegravir could have a “useful” role in HIV post-exposure
prophylaxis, according to investigators from the US writing in the online
edition of the Journal of Acquired Immune
Deficiency Syndromes. 
Doctors in Boston, Massachusetts, prescribed a post-exposure
prophylaxis (PEP) regimen of raltegravir (Isentress)
with tenofovir and FTC (Truvada) to
100 patients after possible sexual exposure to HIV.</description>
      <link>http://www.aidsmap.com/RaltegraviriTruvadai-HIV-PEP-regimen-well-tolerated-with-no-infections-after-its-use/page/2227321/</link>
      <category>Must see</category>
      <category>PEP</category>
      <category>United States</category>
      <author>Michael Carter</author>
      <guid isPermaLink="True">http://www.aidsmap.com/RaltegraviriTruvadai-HIV-PEP-regimen-well-tolerated-with-no-infections-after-its-use/page/2227321/</guid>
      <pubDate>Tue, 31 Jan 2012 08:10:00 GMT</pubDate>
    </item>
    <item>
      <title>For study participants, PrEP was an opportunity to save their relationship</title>
      <description>Seeking to understand why adherence to pre-exposure
prophylaxis (PrEP) was extremely high in a study of serodiscordant couples,
qualitative researchers have found that trial participants saw PrEP as a way
they could preserve their relationship despite the pressures created by the
knowledge of different HIV status and the risk of infection. In an article
published</description>
      <link>http://www.aidsmap.com/For-study-participants-PrEP-was-an-opportunity-to-save-their-relationship/page/2229616/</link>
      <category>Adherence</category>
      <category>Must see</category>
      <category>PrEP</category>
      <category>Relationships and feelings</category>
      <category>Telling people you have HIV</category>
      <category>Uganda</category>
      <author>Roger Pebody</author>
      <guid isPermaLink="True">http://www.aidsmap.com/For-study-participants-PrEP-was-an-opportunity-to-save-their-relationship/page/2229616/</guid>
      <pubDate>Mon, 30 Jan 2012 10:00:00 GMT</pubDate>
    </item>
    <item>
      <title>Majority of HIV-positive patients in US not receiving regular medical care</title>
      <description>Only 45% of
HIV-positive patients in the US are receiving regular medical monitoring,
research published in the online edition of the Journal of Acquired Immune Deficiency Syndromes suggests. 
The study also showed
that a third of patients were not being linked with specialist HIV care within
the first year of their diagnosis with the</description>
      <link>http://www.aidsmap.com/Majority-of-HIV-positive-patients-in-US-not-receiving-regular-medical-care/page/2228542/</link>
      <category>Delivery of care</category>
      <category>Must see</category>
      <category>United States</category>
      <author>Michael Carter</author>
      <guid isPermaLink="True">http://www.aidsmap.com/Majority-of-HIV-positive-patients-in-US-not-receiving-regular-medical-care/page/2228542/</guid>
      <pubDate>Mon, 30 Jan 2012 08:10:00 GMT</pubDate>
    </item>
    <item>
      <title>Hormonal contraception and HIV risk: no increased risk in South African cohort</title>
      <description>During a study of 5567 South African women, looking at the effect of hormonal contraception on HIV acquisition, 270 women became HIV-infected. The researchers report that use
of hormonal contraception did not increase the risk, overall, of becoming HIV positive,
compared to non-hormonal contraception, in the advance online
edition of AIDS. 
 There</description>
      <link>http://www.aidsmap.com/Hormonal-contraception-and-HIV-risk-no-increased-risk-in-South-African-cohort/page/2229309/</link>
      <category>Contraception</category>
      <category>Microbicides</category>
      <category>Transmission and prevention</category>
      <author>Carole Leach-Lemens</author>
      <guid isPermaLink="True">http://www.aidsmap.com/Hormonal-contraception-and-HIV-risk-no-increased-risk-in-South-African-cohort/page/2229309/</guid>
      <pubDate>Thu, 26 Jan 2012 14:10:00 GMT</pubDate>
    </item>
    <item>
      <title>Rapid HIV test performance poorer with oral fluid than blood, especially when prevalence is low</title>
      <description>The
performance of OraQuick, a widely used rapid point-of-care test for HIV
diagnosis, is slightly poorer when testing oral fluid samples than when testing
blood samples, according to a meta-analysis published in the online edition of
Lancet Infectious Diseases this week.The authors also found that if the test
is used in low-prevalence settings with oral</description>
      <link>http://www.aidsmap.com/Rapid-HIV-test-performance-poorer-with-oral-fluid-than-blood-especially-when-prevalence-is-low/page/2228132/</link>
      <category>Must see</category>
      <category>Types of tests</category>
      <author>Roger Pebody</author>
      <guid isPermaLink="True">http://www.aidsmap.com/Rapid-HIV-test-performance-poorer-with-oral-fluid-than-blood-especially-when-prevalence-is-low/page/2228132/</guid>
      <pubDate>Wed, 25 Jan 2012 15:30:00 GMT</pubDate>
    </item>
  </channel>
</rss>
